Business Context and Reporting Period
Aethlon Medical, Inc. (AEMD), a Nevada corporation, filed this Form 8-K on September 4, 2025, to report the entry into a Material Definitive Agreement. The filing details a registered public offering that closed on September 5, 2025.
Key Financial Metrics
- Gross Proceeds: $4.5 million from the sale of Common Units.
- Net Proceeds: Approximately $3.9 million after deducting placement agent fees, expenses, and estimated offering costs.
- Placement Agent Fees: $281,250 cash fee (6.25% of gross proceeds) plus $100,000 for expense reimbursement.
- Use of Proceeds: Working capital for general corporate purposes.
- Revenue/Profit/Cash Flow: The filing text does not provide a clear value for operating revenue, net income, operating cash flow, or margins as this is a transaction report, not a periodic financial statement.
Material Changes and Transaction Details
The Company completed a public offering of Common Units at a price of $0.90 per unit. Each unit consists of one share of Common Stock (or a Pre-Funded Warrant) and one Common Warrant. The specific securities issued include:
- 4,047,780 shares of Common Stock.
- 952,220 Pre-Funded Warrants.
- 5,000,000 Common Warrants (exercisable immediately at $0.90/share).
- 200,000 Placement Agent Warrants (exercisable after 6 months at $0.90/share).
Maxim Group LLC served as the exclusive placement agent. The Company also entered into a Warrant Agency Agreement with Computershare Inc.
Restrictions and Covenants
- Issuance Moratorium: The Company agreed not to issue or announce the issuance of securities for 90 days post-closing, with exceptions.
- Variable Rate Transaction Ban: No variable rate transactions for one year post-closing.
- Lock-Up Agreements: Officers and directors agreed not to sell or transfer securities for 60 days post-closing.
Guidance, Outlook, and Risks
The filing does not contain specific financial guidance, forward-looking revenue projections, or management commentary regarding future operational performance beyond the stated intent to use proceeds for working capital. The primary risks and contingencies noted are the customary conditions to closing, representations and warranties, and the dilution impact of the warrant exercises.
Investor Verification Checklist
- Verify the final number of shares issued versus the 4,047,780 shares and 952,220 Pre-Funded Warrants listed in the summary.
- Confirm the exact net proceeds received after all offering expenses are finalized.
- Review the full text of the Securities Purchase Agreement (Exhibit 10.1) for specific termination rights and indemnification obligations.
- Monitor the 60-day lock-up expiration for officers and directors to assess potential selling pressure.
- Check the exercise terms of the 5.2 million total warrants issued to understand future dilution potential.